Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

[cafead]

via

• Pfizer, GSK, and Moderna are the leaders in the race to market RSV vaccines.
• There's a serious unmet need with RSV causing health issues for older adults and children.
• Pfizer should be a big winner in RSV, but it could have a lower market share than GSK.

article source